Pathophysiology
Clinical meaning
Beta-agonist bronchodilators act on beta-2 adrenergic receptors (B2ARs) expressed on airway smooth muscle cells, mast cells, and airway epithelium. B2ARs are G-protein coupled receptors linked to stimulatory G-proteins (Gs). Upon beta-agonist binding, Gs activates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA), which phosphorylates myosin light chain kinase (MLCK), reducing its affinity for the calcium-calmodulin complex and causing smooth muscle relaxation (bronchodilation). Additionally, PKA activates BK(Ca) potassium channels causing membrane hyperpolarization and inhibits IP3-mediated calcium release from the sarcoplasmic reticulum. Short-Acting Beta-Agonists (SABAs) such as albuterol have rapid onset (5-15 minutes) and short duration (4-6 hours). They are rescue medications for acute bronchospasm. The NP must understand that SABA overuse (more than 2 days per week or more than 2 canisters per year) indicates poorly controlled asthma requiring controller therapy escalation per GINA/NAEPP guidelines. Long-Acting Beta-Agonists (LABAs) such as salmeterol and formoterol provide 12-hour bronchodilation through lipophilic side chains that anchor in the cell membrane near the receptor, allowing prolonged receptor stimulation. FDA BLACK BOX WARNING: LABAs must NEVER be used as monotherapy in...